Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · IEX Real-Time Price · USD
13.03
+0.03 (0.23%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Takeda Pharmaceutical Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for TAK.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Takeda Pharmaceutical.
Recommendation Trends
Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 1 | 0 |
Buy | 1 | 1 | 1 | 1 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
TD Cowen | TD Cowen | Buy Maintains $30 → $20 | Buy | Maintains | $30 → $20 | +53.49% | May 16, 2023 |
TD Cowen | TD Cowen | Buy Maintains $24 → $30 | Buy | Maintains | $24 → $30 | +130.24% | Apr 4, 2023 |
B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $20 | Hold → Strong Buy | Upgrades | $20 | +53.49% | Mar 16, 2023 |
Cowen & Co. | Cowen & Co. | Hold → Buy Upgrades $21 → $24 | Hold → Buy | Upgrades | $21 → $24 | +84.19% | Jul 19, 2022 |
Financial Forecast
Revenue This Year
4,306.00B
from 4,263.76B
Increased by 0.99%
Revenue Next Year
4,378.64B
from 4,306.00B
Increased by 1.69%
EPS This Year
94.91
from 45.58
Increased by 108.22%
EPS Next Year
148.46
from 94.91
Increased by 56.43%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | 4.6T | 4.8T | 4.9T |
Avg | 4.3T | 4.4T | 4.5T |
Low | 3.9T | 3.9T | 3.9T |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | 8.5% | 10.5% | 13.0% |
Avg | 1.0% | 1.7% | 2.1% |
Low | -8.6% | -8.8% | -11.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | 185.85 | 234.17 | 325.30 |
Avg | 94.91 | 148.46 | 196.51 |
Low | 40.18 | 48.02 | 58.80 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | 307.7% | 146.7% | 119.1% |
Avg | 108.2% | 56.4% | 32.4% |
Low | -11.8% | -49.4% | -60.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.